Mumbai healthtech funding falls 31% in H1 2026 as large rounds shrink

Funding decline in Mumbai and India

According to Inc42, Mumbai-based healthtech startups raised $587 million across 60 deals in the first half of 2026, a 31% year-on-year drop in value. This reflects a wider slowdown, with India’s total startup funding declining 9% to $5.2 billion across 501 deals during the same period.

Nationally, only four rounds of $100 million or more closed in H1 2026, down from 11 a year earlier. This contraction in large cheques has affected Mumbai’s funding landscape, particularly for late-stage startups.

Sector ranking and projections

India’s healthtech sector slipped from fourth to eighth in terms of capital raised, securing about $700 million across 54 deals in 2025, compared to 78 deals in 2024. Despite this decline, Datalabs projects the sector to grow at a 39% compound annual growth rate (CAGR) to $37 billion by 2030.

Mumbai’s healthtech ecosystem spans diagnostics, insurance-linked care, online pharmacy, and hospital software, with startups like PharmEasy and Medikabazaar leading the city’s funding tables.

Top-funded startups in Mumbai

PharmEasy leads Mumbai’s healthtech funding with $1.96 billion raised, followed by Piramal Group ($771.89 million) and Medikabazaar ($192.55 million). Ascent Health & Wellness Solutions ($181.26 million) and Truemeds ($176.47 million) round out the top five.

Other notable startups include Qure AI ($125.33 million), Toothsi ($86.99 million), and Generico ($44.79 million), reflecting a mix of online pharmacy, diagnostics, and AI-driven health solutions.

Policy support for startups

Maharashtra’s startup framework aims to catalyse INR 5,000 crore in early-stage funding and offers patent-filing incentives, including rebates of up to 80%. These measures are designed to attract and retain innovators in the state.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Mumbai’s healthtech funding slowdown is a microcosm of India’s broader capital crunch. For founders and operators, the shift from growth-at-all-costs to unit economics is now non-negotiable. The drop in $100 Mn+ rounds signals that late-stage investors are sitting on the sidelines, which trickles down to Series A and B valuations. Healthtech startups that once led sector tables are now ranking eighth, so early-stage teams must prove burn discipline and revenue visibility sooner.

The 39% CAGR projection to $37 Bn by 2030 still makes healthtech one of India’s most promising sectors, but the runway is longer. Founders who rely on quick scale rounds will struggle; those who control cash and focus on gross margins will dictate the next chapter. Policy support like Maharashtra’s patent rebates helps, but it won’t replace fundamentals.

Key takeaways

• $100 Mn+ rounds in India dropped from 11 in H1 2025 to four in H1 2026, signalling tighter late-stage checks.
• Healthtech fell from fourth to eighth in sector capital raised, forcing founders to stretch runways and prioritise unit economics.
• Maharashtra’s 80% patent-filing rebate and INR 5,000 Cr early-stage target could offset some funding pressure for local teams.